CD4 and neoplasm: Antibody-mediated T cell depletion revealed that both CD4+ and CD8+ T cell subsets were necessary to reject the tumor indicating that the antitumor effect of artLCMV-TRP2 treatment was mediated by TRP2-specific T cells (Fig. 1f and Supplementary Fig. 1c).